 Since novel inherited and acquired prothrombotic abnormalities are currently under investigation, clinicians often address the question of prophylaxis in women with RPL who do not have a specific thrombophilic defect. The encouraging results presented above let rise the clinical practise of LMWH therapy without the proved evidence in women without thrombophilic disorders. To give the basis for a rational therapy this question should be answered by this prospective randomized trial. 